Investigation and analysis of influencing factors related to financial burden among pulmonary artery hypertension patients

doi:10.3761/j.issn.0254-1769.2023.14.010

Abstract

Abstract:

Objective To investigate subjective and objective financial burden and its correlation with health-related quality of life（HRQOL） among pulmonary artery hypertension（PAH） patients. Methods From February to September 2022，we conducted convenience sampling method to select PAH patients who were followed up in a tertiary hospital，using General Information Questionnaire，Comprehensive Score for Financial Toxicity Functional Assessment of Chronic Illness Therapy（COST），and PAH-specific HRQOL measurement（EmpPHasis-10）. Logistic regression model was used to analyze the independent influencing factors. Results 152 PAH patients were included，and 123（80.9%） patients experienced financial burden，and the mean score of subjective financial burden was 16.22±10.19. The multivariate linear regression analysis showed that pulmonary artery systolic pressure（PASP），6 minute walk distance（6MWD），social-economic status，catastrophic health care expenditures，and cost-related medication nonadherence（CRNA） were influencing factors of financial burden，which accounted 42.9% of the total variation. Financial burden was correlated with EmpPHasis-10（P<0.05）. Conclusion The subjective and objective financial burden of PAH patients were common，and the HRQOL of patients with high financial burden level was seriously impaired. Medical staff should pay attention to and comprehensively screen the financial burden to prevent patients from becoming poor due to disease in the stage of disease management，so as to reduce the impact of financial burden on patients’ prognosis.

Key words: Pulmonary Artery Hypertension, Financial Burden, Health-Related Quality of Life, Correlation, Nursing Care

摘要：

目的调查肺动脉高压患者的主、客观经济负担现状，并探讨其与健康相关生活质量的相关性。方法采取便利抽样法，选取2022年2月—9月在北京市某三级甲等医院就诊的肺动脉高压患者作为调查对象。使用一般资料调查表、慢性病治疗经济毒性功能评估综合评分（Comprehensive Score for Financial Toxicity Functional Assessment of Chronic Illness Therapy，COST）和肺动脉高压特异性健康相关生活质量量表等对患者进行调查，并分析其影响因素。结果 152例肺动脉高压患者中，123例（80.9%）存在经济负担，COST为（16.22±10.19）分；多元线性逐步回归结果显示，肺动脉收缩压、6 min步行距离、社会经济地位复合指数、灾难性医疗支出和经济相关服药不依从是肺动脉高压患者经济负担的影响因素，可解释总变异的42.9%。经济负担与健康相关生活质量存在相关性（P<0.05）。结论肺动脉高压患者主、客观经济负担普遍存在，经济负担大的患者健康相关生活质量受损严重，医护人员应重视并全面筛查患者的经济负担，防止患者在疾病管理阶段因病致贫，从而减轻经济负担对患者预后的不良影响。

关键词: 肺动脉高压, 经济负担, 健康相关生活质量, 相关性, 护理

JIANG Ying, YU Minhong, ZHANG Chunyan, KANG Xiaofeng. Investigation and analysis of influencing factors related to financial burden among pulmonary artery hypertension patients[J]. Chinese Journal of Nursing, 2023, 58(14): 1733-1741.

江莹, 余旻虹, 张春燕, 康晓凤. 肺动脉高压患者经济负担影响因素分析及护理对策[J]. 中华护理杂志, 2023, 58(14): 1733-1741.

Figures/Tables 4

Table 1 The general information of the subjects and the results of the univariate analysis on the influencing factors of financial burden（n=152）

Table 2 Assignment of included variables

Table 3 Multivariable linear stepwise regression analysis of financial burden（n=152）

Table 4 Correlation of financial burden and health-related quality of life

References 27

[1]	Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS gui-delines for the diagnosis and treatment of pulmonary hypertension[J]. Eur Respir J, 2023, 61(1):2200879. DOI URL
[2]	Omura J, Habbout K, Shimauchi T, et al. Identification of long noncoding RNA H19 as a new biomarker and therapeutic target in right ventricular failure in pulmonary arterial hypertension[J]. Circulation, 2020, 142(15):1464-1484. DOI URL
[3]	中国新闻网. 《中国肺动脉高压患者生存现状白皮书》发布:揭示患者群体诊疗现状[EB/OL]. (2021-04-30)[2023-01-08]. https://baijiahao.baidu.com/s?id=1698478040776411284&wfr=spider&for=pc.
	China News. 《White Book on Pulmonary Artery Hypertension Patients》released:to reveal the status of diagnosis and treatment in patient groups[EB/OL].(2021-04-30)[2023-01-08]. https://baijiahao.baidu.com/s?id=1698478040776411284&wfr=spider&for=pc.
[4]	Piette JD, Heisler M, Horne R, et al. A conceptually based approach to understanding chronically ill patients’ responses to medication cost pressures[J]. Soc Sci Med, 2006, 62(4):846-857. DOI PMID
[5]	吴文汇. 中国肺动脉高压患者社会经济地位与其疾病严重程度和生存的相关性研究[D]. 上海: 同济大学, 2012.
	Wu WH. Correlation between socio-economic status and disease severity and survival of patients with pulmonary hypertension in China[D]. Shanghai: Tongji University, 2012.
[6]	中华医学会呼吸病学分会肺栓塞与肺血管病学组, 中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会, 全国肺栓塞与肺血管病防治协作组, 等. 中国肺动脉高压诊断与治疗指南(2021版)[J]. 中华医学杂志, 2021, 101(1):11-51.
	Pulmonary Embolism and Pulmonary Vascular Disease Group of Respiratory Medicine Branch of Chinese Medical Association,Pulmonary Embolism and Pulmonary Vascular Disease Working Committee of Respiratory Physician Branch of Chinese Medical Doctor Association, National Cooperative Group for Prevention and Treatment of Pulmonary Embolism and Pulmonary Vascular Disease, et al. Guidelines for diagnosis and treatment of pulmonary hypertension in China(2021 edition)[J]. Natl Med J China, 2021, 101(1):11-51.
[7]	姚静静, 王海鹏, 孙强. 山东省2型糖尿病患者自付医疗费用和疾病经济风险现状分析[J]. 中国卫生政策研究, 2019, 12(7):75-80.
	Yao JJ, Wang HP, Sun Q. Analysis of the status of self-paid medical expenses and disease economic risks among T2MD patients in Shandong province[J]. Chin J Health Policy, 2019, 12(7):75-80.
[8]	Rijal A, Adhikari TB, Khan JAM, et al. The economic impact of non-communicable diseases among households in South Asia and their coping strategy:a systematic review[J]. PLoS One, 2018, 13(11):e0205745. DOI URL
[9]	WHO. Designing health financing systems to reduce catastro-phic health expenditure[EB/OL].[2023-01-08]. https://www.who.int/health_financing/documents/pb_e_05_2-cata_sys.pdf.
[10]	Piette JD, Heisler M, Wagner TH. Cost-related medication underuse among chronically ill adults:the treatments people forgo,how often,and who is at risk[J]. Am J Public Health, 2004, 94(10):1782-1787. DOI PMID
[11]	Pierre-Jacques M, Safran DG, Zhang F, et al. Reliability of new measures of cost-related medication nonadherence[J]. Med Care, 2008, 46(4):444-448. DOI PMID
[12]	de Souza JA, Yap BJ, Hlubocky FJ, et al. The development of a financial toxicity patient-reported outcome in cancer:the COST measure[J]. Cancer, 2014, 120(20):3245-3253. DOI URL
[13]	于慧会, 毕雪, 刘运泳. 中文版癌症患者报告结局的经济毒性量表信度和效度研究[J]. 中华流行病学杂志, 2017, 38(8):1118-1120. PMID
	Yu HH, Bi X, Liu YY. Reliability and validity of the Chinese version on Comprehensive Scores for Financial Toxicity based on the patient-reported outcome measures[J]. Chin J Epidemiol, 2017, 38(8):1118-1120. DOI PMID
[14]	Yorke J, Corris P, Gaine S, et al. EmPHasis-10:development of a health-related quality of life measure in pulmonary hypertension[J]. Eur Respir J, 2014, 43(4):1106-1113. DOI URL
[15]	陈月香, 孙国珍. 中文版肺高压疾病特异性量表的心理测量学特征评价[J]. 护士进修杂志, 2017, 32(5):396-399.
	Chen YX, Sun GZ. Evaluation of psychometric characteristics of Chinese Version Scale for Patients with Pulmonary Hypertension[J]. J Nurses Train, 2017, 32(5):396-399.
[16]	Shi Y, Dong XB, Hu XY, et al. Cross-cultural validation of the Chinese version of the EmPHasis-10 questionnaire in connective tissue disease patients with pulmonary arterial hypertension and its relationship with risk stratification[J]. BMC Pulm Med, 2022, 22(1):264. DOI PMID
[17]	袁潇逸, 孙艳玲, 况艺, 等. 乳腺癌生存者经济毒性现状与影响因素分析[J]. 中国护理管理, 2022, 22(6):830-835.
	Yuan XY, Sun YL, Kuang Y, et al. Status and influencing factors of cancer-related financial toxicity of breast cancer survivors[J]. Chin Nurs Manag, 2022, 22(6):830-835.
[18]	袁方, 林梦月, 刘永珍, 等. 前列腺癌患者经济负担现状及影响因素分析[J]. 中华护理杂志, 2022, 57(8):918-925. DOI URL
	Yuan F, Lin MY, Liu YZ, et al. The analysis of the financial toxicity and its influencing factors in prostate cancer patients[J]. Chin J Nurs, 2022, 57(8):918-925. DOI URL
[19]	Zhai ZG, Zhou X, Zhang S, et al. The impact and financial burden of pulmonary arterial hypertension on patients and caregivers:results from a national survey[J]. Medicine (Baltimore), 2017, 96(39):e6783. DOI URL
[20]	Housten-Harris T. The nurse specialist and practical issues in the care of pulmonary arterial hypertension patients[J]. Int J Clin Pract Suppl, 2007(158):10-18.
[21]	阮君怡, 刘城, 况艺, 等. 年轻女性乳腺癌生存者经济毒性应对策略的质性研究[J]. 军事护理, 2022, 39(8):29-33.
	Ruan JY, Liu C, Kuang Y, et al. Coping strategies for financial toxicity in young female breast cancer survivors:a qualitative study[J]. Mil Nurs, 2022, 39(8):29-33.
[22]	Carrera PM, Kantarjian HM, Blinder VS. The financial burden and distress of patients with cancer:understanding and stepping-up action on the financial toxicity of cancer treatment[J]. CA Cancer J Clin, 2018, 68(2):153-165. DOI URL
[23]	Chan RJ, Gordon LG, Tan CJ, et al. Relationships between financial toxicity and symptom burden in cancer survivors:a systematic review[J]. J Pain Symptom Manage, 2019, 57(3):646-660.e1. DOI URL
[24]	Zafar SY, Peppercorn JM, Schrag D, et al. The financial toxicity of cancer treatment:a pilot study assessing out-of-pocket expenses and the insured cancer patient’s experience[J]. Oncologist, 2013, 18(4):381-390. DOI URL
[25]	Bouberhan S, Shea M, Kennedy A, et al. Financial toxicity in gynecologic oncology[J]. Gynecol Oncol, 2019, 154(1):8-12. DOI PMID
[26]	Ting CY, Teh GC, Yu KL, et al. Financial toxicity and its associations with health-related quality of life among urologic cancer patients in an upper middle-income country[J]. Support Care Cancer, 2020, 28(4):1703-1715. DOI PMID
[27]	焦延超, 刘化侠, 石红伟, 等. 癌症患者自我感受负担相关因素的研究进展[J]. 中华护理杂志, 2012, 47(5):473-475.
	Jiao YC, Liu HX, Shi HW, et al. The related factors of self-perceived burden in cancer patients:a literature review[J]. Chin J Nurs, 2012, 47(5):473-475.